Posts

Posted on

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ingredion (INGR)

Ingredion shares fell after management tied a lowered full-year outlook to a slower-than-expected earnings recovery at its Argo facility, where an April 2026 thermal event occurred. Levi & Korsinsky is investigating potential securities law violations concerning the Company’s statements about its Argo operations

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR) shares fell after the Company cut its full-year adjusted EPS outlook to $9.25-$9.70, with management citing a slower-than-expected earnings recovery at its Argo facility, the plant where a thermal event occurred in April 2026. If you bought INGR and are now holding a loss, you have legal rights. Investors who suffered losses are encouraged to submit their INGR loss details now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Argo has appeared repeatedly in Ingredion’s reports this year. The Q1 2026 Form 10-Q, filed May 8, 2026, showed Food & Industrial Ingredients-U.S./Canada segment operating income down 63%. That filing cited “production challenges at our Argo facility” and disclosed the April thermal event. Second-quarter results followed with U.S./Canada operating income down 33% on “lower production at our Argo facility.”

The Company now projects flat full-year sales and adjusted operating income down in the mid-teens. Levi & Korsinsky is investigating potential securities law violations concerning Ingredion’s statements about its Argo operations.

Shareholders who lost money on Ingredion stock can request a free review of their INGR losses or call (212) 363-7500 today.

WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered billions of dollars for investors.

Frequently Asked Questions About the INGR Investigation

Q: Who is eligible to participate in the INGR investigation? A: Investors who purchased INGR stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Ingredion made materially false or misleading statements regarding operations and the earnings recovery at its Argo facility. When the Company disclosed a slower-than-expected earnings recovery at Argo and lowered its full-year adjusted EPS outlook to $9.25-$9.70, the stock price declined.

Q: When did Ingredion allegedly mislead investors? A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What do INGR investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my INGR shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought INGR and sold at a loss may still participate in the investigation.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.



Posted on

BIDU Investors Have Opportunity to Lead Baidu, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Nov. 12, 2026 (GLOBE NEWSWIRE) — Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baidu, Inc. (“Baidu” or “the Company”) (NASDAQ: BIDU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of BIDU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: November 18, 2025 to August 17, 2026

DEADLINE: November 13, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Baidu overstated the ability of its AI business to cover the rapid decline in its legacy marketing business. The Company was likely to suffer a decline in revenue. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Baidu, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. 

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

 Schall, Brown & Schwartz LLP



Posted on

DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years

Châtillon, France, November 12, 2026

DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN

®

Peanut Patch in Children Ages 4-7 Years

  • Additional VITESSE data being presented at 2026 ACAAI Annual Scientific Meeting support safety and efficacy findings from the phase 3 study, and assess potential practical aspects of daily use if approved
  • VIASKIN® Peanut Patch treatment was associated with statistically significant reductions in reaction severity during the double-blind, placebo-controlled food challenges after 12 months, including reductions when reactions were assessed at or below participants’ baseline eliciting dose
  • Mean treatment compliance was 96.1%; most study participants reported patches were easy and not painful to remove, and no restrictions on daily activities or concomitant medications were required in the study protocol
  • VITESSE participants receiving the VIASKIN® Peanut Patch had immunologic changes consistent with allergen immunotherapy, including increased peanut-specific IgG4 and decreased peanut-specific IgE, Ara h 2 IgE and skin-prick-test wheal diameter

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that new data from the successful Phase 3 VITESSE clinical trial of the VIASKIN® Peanut Patch in peanut-allergic children aged 4 to 7 years were highlighted in three presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. The three presentations evaluate changes in allergic reaction severity during double-blind, placebo-controlled food challenges, the potential practicality of the VIASKIN® Peanut Patch using epicutaneous immunotherapy (EPIT), and changes to immunologic biomarkers during the 12-month VITESSE study.

VITESSE, the largest food allergy immunotherapy trial to date, randomized 654 children 2:1 to receive the VIASKIN Peanut Patch containing 250 µg of peanut protein (VP250) or placebo for 12 months. The study met its primary endpoint, with 46.6% of children in the VIASKIN Peanut Patch arm meeting treatment responder criteria at month 12 compared with 14.8% in the placebo arm (difference in response rates = 31.8%; 95% confidence interval [CI]: 24.5%, 39.0%; p<0.001).

“The VITESSE data presented at ACAAI add important context to the study’s overall positive results,”
said Pharis Mohideen, M.D., Chief Medical Officer of DBV Technologies. “After one year of treatment, children receiving the VIASKIN® Peanut Patch in the study had statistically significantly lower maximum symptom severity during food challenge, along with immunologic changes consistent with other forms of allergen immunotherapy. I am also pleased that the practicality data show high treatment compliance in young children with common atopic comorbidities, and that all participants were able to continue their typical daily activities, including bathing, sports and swimming, while on treatment.”

Highlights from the VITESSE data presented at ACAAI 2026:

“Changes in Reaction Severity Following Epicutaneous Immunotherapy in Children with Peanut Allergy”

  • At the month 12 double-blind, placebo-controlled food challenge (DBPCFC), maximum symptom severity was significantly lower with the VIASKIN® Peanut Patch versus placebo (p=0.004). Severe reactions occurred in 8.4% of VIASKIN treated participants versus 12.5% of placebo participants; 12.5% of VIASKIN treated participants had no or mild symptoms versus 1.5% with placebo.
  • When reactions at month 12 were evaluated at or below each participant’s baseline eliciting dose, 52.7% of VIASKIN treated participants had no symptoms versus 19.2% with placebo, while moderate or severe reactions occurred in 14.0% of VIASKIN treated participants versus 50.0% with placebo.

“Immunologic Changes in VITESSE: A 12-Month Study of Epicutaneous Immunotherapy in Children with Peanut Allergy”

  • Peanut-specific IgG4 increased by month 3 with the VIASKIN® Peanut Patch and remained elevated through month 12
  • At month 12, median peanut-specific IgE and Ara 2-specific IgE were significantly lower with the VIASKIN® Peanut Patch versus placebo (p=0.001).
  • Mean skin-prick-test wheal diameter decreased significantly with the VIASKIN® Peanut Patch versus placebo at month 12 (least-squares mean ratio: 0.74; 95% CI: 0.69, 0.79; p<0.0001).
  • VIASKIN® Peanut Patch treatment for one year resulted in statistically significant greater responder rates versus placebo and immunomodulatory changes consistent with other forms of allergen immunotherapy.

“Practicality of Daily Epicutaneous Immunotherapy in Young Children with Peanut Allergy”

  • Mean treatment compliance was high in both groups (96.1% with the VIASKIN® Peanut Patch and 96.5% with placebo).
  • Most patches were rated by participants as “very easy” or “easy” to remove (83.4% with the VIASKIN® Peanut Patch; 84.8% with placebo) and “not painful” to remove (71.9% with the VIASKIN® Peanut Patch; 70.2% with placebo).
  • Participants continued typical daily activities, including bathing/showering, play, sports and swimming, with no restrictions on daily activities or concomitant medication use required during the study.
  • Atopic comorbidities were common among VITESSE participants, including atopic dermatitis, other food allergies and asthma.

“When I work with families in the clinic, the treatment conversations are not just about safety and efficacy, but practical considerations such as time commitment, how a treatment might fit into family life and family routines, and impact on the child,” 
said Edwin H. Kim, M.D., Associate Professor of Pediatrics at the University of North Carolina School of Medicine.
“These additional data from VITESSE are clinically meaningful and I believe support the potential of the VIASKIN® Peanut Patch to be integrated into the daily routines of children living with peanut allergy, if approved.”

The presentations will be made available on the Scientific Publications & Presentations page on the Company’s website following presentation at the meeting.

About DBV Technologies

DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Forward Looking Statements

This press release may contain forward-looking statements, including statements regarding the therapeutic potential of VIASKIN® Peanut patch and EPIT, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, clinical trial data release and publications, , and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, as amended by the Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026, DBV’s Quarterly Report on Form 10-Q filed with the SEC on October 28, 2026, and future filings and reports made with the SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Contact

Virginie Boucinha
DBV Technologies
[email protected]

Media Contact

Brett Whelan
DBV Technologies
[email protected]

Attachment



Posted on

Brunswick Corporation Wins Best of Show, Three Additional Honors at 2026 In-House Creative Awards

“The Voice of Lowrance” campaign wins Best of Show; Boston Whaler brand refresh and Lowrance Bassmaster Classic also recognized for creative excellence

METTAWA, Ill. , Nov. 12, 2026 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC), a global leader in recreational marine technology, today announced that its internal creative team received four honors at the 2026 In-House Creativity Awards, presented by the In-House Agency Forum (IHAF). The honors include the competition’s prestigious Best of Show award for Lowrance’s “Voice of Lowrance” campaign.

The awards were presented Nov. 10 at the IHAF Conference & Awards in Boston. The annual In-House Creativity Awards recognize outstanding creative work produced by corporate creative organizations and in-house agencies.

“Lowrance and Boston Whaler are two of the most iconic and storied brands in the marine industry, and continuing to build their legacies requires both a deep respect for their heritage and a willingness to push creative boundaries,” said Lauren Beckstedt, senior vice president and chief marketing officer, Brunswick Corporation. “These awards recognize the passion, imagination and creative excellence our team brings to building meaningful brands and brand experiences. Earning Best of Show is especially rewarding and reflects the exceptional talent we have brought together within Brunswick.”

Brunswick’s 2026 In-House Creativity Awards

  • Best of Show, Creative Copywriting: “
    The Voice of Lowrance
    ,” an integrated advertising campaign celebrating Lowrance’s connection with anglers and fishing culture.
  • Gold, Creative Copywriting: “The Voice of Lowrance.”  Watch “The Voice of Lowrance.”
  • Silver, Events, B2C, External Audience: Lowrance Bassmaster Classic, recognizing a creative partnership with a local brewery.
  • Honorable Mention, Corporate Communications, Brand Identity Kits:
    Boston Whaler brand refresh, recognizing creative work to modernize the expression of one of the marine industry’s most recognizable brands. Watch the Boston Whaler brand refresh video.

“These awards are a tremendous honor for our entire creative team and a reflection of the talent, dedication and collaboration behind every project,” said Alli Straus, senior director of creative services, Brunswick Corporation. “Our team brings an incredible amount of passion and pride to the work, and having that creativity recognized by our peers in the industry is especially meaningful. It’s a testament to what we can accomplish when talented people come together around a shared commitment to great ideas and exceptional execution.”

The In-House Creativity Awards recognize outstanding creative work produced by internal agencies across more than 40 categories, including advertising, corporate identity, social media, video and experiential marketing. Entries are evaluated by a panel of industry experts, with Gold, Silver and Honorable Mention awards presented across individual categories and a single Best of Show honor awarded across the competition.

The four honors highlight Brunswick’s investment in building marketing and creative capabilities internally, combining brand expertise with creative innovation to strengthen consumer connections across its portfolio.

About Brunswick

Brunswick Corporation (NYSE: BC) is a global leader in marine recreation, delivering innovation that transforms experiences on the water and beyond. Its technology-driven solutions are informed by deep consumer insights and guided by the belief that “Next Never Rests™.” Brunswick is home to more than 60 industry-leading brands across marine propulsion, parts and accessories, marine electronics, as well as boat brands including Boston Whaler, Sea Ray, Bayliner, Lund and Harris. Headquartered in Mettawa, Illinois, Brunswick has approximately 14,000 employees operating in 26 countries. For more information, visit Brunswick.com or the Brunswick Newsroom

### 



Brad Carroll
Director, External Enterprise Communication
734-751-3088
[email protected]

Posted on

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

  • Among patients previously on long-term prophylaxis (LTP) in HAELO Phase 3 trial, monthly attack rate decreased by 81% following lonvo-z dosing compared with prior LTP
  • 100% of patients receiving 50 mg of lonvo-z across Phase 1/2 clinical trial and HAELO were LTP-free as of the data cutoffs
  • Among 23 Phase 1/2 patients interviewed, all described their hereditary angioedema (HAE) as well controlled after receiving lonvo-z and 22 (96%) reported lonvo-z as an optimal HAE therapy
  • Intellia hosting investor webcast today at 10:00 a.m. ET

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced highlights from its seven presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. Intellia will host an investor webcast today at 10:00 a.m. ET to review certain data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE.

Oral Presentation Details:

  • Title: Four-Year Durability/Safety of Lonvoguran Ziclumeran (Lonvo-z) 50 mg in Patients with Hereditary Angioedema
    Session: Distinguished Industry and Late-Breaking Oral Abstracts – Session 2
    Date and Time: Saturday, November 14, 2026, from 4:43 – 4:53 p.m. MT
    Presenter: Danny Cohn, M.D., Ph.D., Associate Professor, Amsterdam University Medical Center, Department of Vascular Medicine, University of Amsterdam; Phase 1/2 and HAELO principal investigator

    • In the Phase 1/2 study, deep, consistent and durable reductions in plasma kallikrein were observed in all patients, with a mean reduction of 84% at four weeks that was maintained through up to four years of follow-up. Lonvo-z continues to be well tolerated with no new long-term risks identified.
    • Additional biomarkers were reported that support lonvo-z’s intended mechanism of action in which inactivation of the KLKB1 gene and the associated reduction in plasma kallikrein protein leads to reduced activity of the kallikrein-kinin system and less bradykinin production.
  • Title: Attack-Free and Long-Term Prophylaxis-Free Status Following Treatment with Lonvoguran Ziclumeran in Hereditary Angioedema
    Session: Distinguished Industry and Late-Breaking Oral Abstracts – Session 2
    Date and Time: Saturday, November 14, 2026, from 4:53 – 5:03 p.m. MT
    Presenter: Emel Aygören-Pürsün, M.D., Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University; Phase 1/2 and HAELO principal investigator

    • In the Phase 1/2 study (n=32), following a one-time 50 mg dose of lonvo-z, the proportion of patients who were attack-free after one year was at least 90% during each month with up to 4 years of follow-up. Additionally, 100% of patients were LTP-free as of the data cutoff.
    • The estimated probability of beginning an attack-free and LTP-free interval lasting >6 months increased from 81% at six months to 93% at 24 months post-dosing.

Poster Presentation Details: 

  • Title: Lonvoguran Ziclumeran Demonstrated Consistent Benefit in All Hereditary Angioedema Patient Subgroups in Ph3 HAELO Study
    Poster Session: Monitor 17
    Date and Time: Friday, November 13, 2026, from 3:05 – 3:20 p.m. MT
    Presenter: Marc Riedl, M.D., Professor of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center, University of California San Diego; HAELO principal investigator

    • Among the 35 HAELO patients taking LTP at study entry who were randomized to the lonvo-z arm, the mean HAE attack rate decreased by 81% during the efficacy observation period when compared to the attack rate while on prior LTP. Following lonvo-z treatment, 63% of these patients achieved complete control, more than tripling the attack-free rate while on prior LTP.
    • All prespecified subgroups demonstrated consistent benefit in attack rate reduction favoring lonvo-z over placebo regardless of disease severity or prior LTP treatment. All treatment emergent adverse events (TEAEs) were mild or moderate and there were no serious adverse events observed in the lonvo-z arm.
  • Title: Lived Experiences of Patients Treated with Lonvoguran Ziclumeran, a One-Time CRISPR Treatment for Hereditary Angioedema
    Poster Session: Monitor 17
    Date and Time: Friday, November 13, 2026, from 3:20 – 3:35 p.m. MT
    Presenter: Padmalal Gurugama, MBBS, M.S., M.D., MRCP, FRCPath, Consultant, Clinical Immunology and Allergy, Cambridge University Hospitals NHS Foundation Trust; Phase 1/2 and HAELO principal investigator

    • In interviews with 23 Phase 1/2 patients with a median of 2.4 years of follow-up since lonvo-z infusion, all reported their HAE was well controlled following lonvo-z, compared with 48% before lonvo-z. Among the 23 patients, 86% changed their definition of well controlled post-treatment, describing the shift from symptom management and medication dependence to having no attacks and reduced treatment burden.
    • Of the 23 patients, 22 (96%) described lonvo-z as an optimal therapy, citing its perceived effectiveness and its potential to serve as a one-time treatment that frees them from ongoing preventive treatment.
  • Title: Long-Term Prophylaxis for Hereditary Angioedema: Treatment Use, Patterns, and Gaps in a U.S. Claims Database
    Poster Session: Monitor 18
    Date and Time: Friday, November 13, 2026, from 4:05 – 4:20 p.m. MT
    Presenter: Raffi Tachdjian, M.D., M.P.H., Associate Clinical Professor of Medicine and Pediatrics, Division of Allergy and Clinical Immunology, David Geffen School of Medicine, University of Los Angeles; HAELO principal investigator

    • In a U.S. claims analysis of 538 HAE patients taking LTP over a median of 1.2 years, almost 40% were found to be non-adherent. HAE attacks were similar in both adherent and non-adherent groups, indicating breakthrough attacks despite being on LTP treatment.
  • Title: A One-Time Treatment of Lonvoguran Ziclumeran Improves Quality of Life in Patients with Hereditary Angioedema
    Poster Session: Monitor 17
    Date and Time: Friday, November 13, 2026, from 4:35 – 4:50 p.m. MT
    Presenter: William Lumry, M.D., Clinical Professor of Internal Medicine, Allergy and Immunology Division, University of Texas Southwestern Medical School, Medical Director, AARA Research Center; HAELO principal investigator

    • HAELO met its key secondary endpoint of change from baseline to week 28 in Angioedema Quality of Life (AE-QoL) total score. Additionally, lonvo-z demonstrated clinically meaningful improvements across all four domains of AE-QoL vs. placebo, with the improvement of quality of life being sustained over time.
    • Patients who received lonvo-z had a 23.5-point mean reduction in AE-QoL total score from baseline to week 28, compared with a 6.5-point mean reduction for placebo. A 6-point reduction on AE-QoL total score is considered to be the threshold for a clinically important difference.
  • Title: Integrated Analysis of Lonvoguran Ziclumeran Phase 1/2/3 Studies in Hereditary Angioedema: Efficacy, Safety, and Tolerability
    Poster Session: Monitor 16
    Date and Time: Friday, November 13, 2026, from 5:35 – 5:50 p.m. MT
    Presenter: Aleena Banerji, M.D., Professor at Harvard Medical School, Director of Clinical Care, Center for Drug and Vaccine Allergy at Massachusetts General Hospital; HAELO principal investigator

    • Of the 93 patients who received a single one-time 50 mg dose of lonvo-z across the Phase 1/2 and Phase 3 HAELO studies, the overall attack rate reduction from baseline was 89% through up to four years of follow-up, and 97% of patients never initiated LTP after treatment. All patients were LTP-free at the latest follow-up.
    • Favorable safety and tolerability data were observed with the most common (>15% of patients) TEAEs being infusion-related reactions, headache, fatigue and nasopharyngitis. No new long-term risks have been identified.

All presentations will be made available on www.intelliatx.com on the Scientific Publications & Presentations page at the start of the respective sessions.

Investor Webcast Reminder

Intellia will host a live webcast on Thursday, November 12, 2026, at 8:00 a.m. MT / 10:00 a.m. ET to review data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE.

To join the webcast, visit the Events page of the Investors & Media section of the company’s website at www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 90 days following the call.

About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting. Lonvo-z has received five notable regulatory designations: Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) Designations by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. In September 2026, the FDA accepted the Biologics License Application (BLA) for lonvo-z and granted Priority Review with a PDUFA target action date of March 10, 2027.

About Hereditary Angioedema

HAE is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks may still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Forward-Looking Statements

This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the success and advancement of its program for lonvoguran ziclumeran or “lonvo-z” (also known as NTLA-2002) for the treatment of hereditary angioedema (“HAE”), including its expectations regarding review and approval of its biologic license application for lonvo-z for the treatment of HAE by the Prescription Drug User Fee Act target action date of March 10, 2027, its expectations regarding any planned U.S. launch of lonvo-z, and the potential of lonvo-z to become the first one-time treatment for HAE and to permanently lower kallikrein by inactivating the KLKB1 gene with a single dose that is administered in an outpatient setting.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z, including risks related to the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.


Investor Contact:


Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]


Media Contact:


Mike Tattory
Vice President
LifeSci Communications
[email protected]



Posted on

Euroseas Ltd. Sets Date for the Release of Third Quarter 2026 Results, Conference Call and Webcast

ATHENS, Greece, Nov. 12, 2026 (GLOBE NEWSWIRE) — Euroseas Ltd. (NASDAQ: ESEA), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today that it will release its financial results for the third quarter ended September 30, 2026, on November 17, 2026 before market opens in New York.

On the same day, Tuesday, November 17, 2026, at 9:30 a.m. Eastern Time, the Company’s management will host a conference call and webcast to discuss the results.

Conference
Call
details:

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877 405 1226 (US Toll-Free Dial In) or +1 201 689 7823 (US and Standard International Dial In). Please quote “Euroseas” to the operator and/or conference ID13763766. Click here for additional participant International Toll -Free access numbers.

Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

Audio
Webcast
–
Slides
Presentation:

There will be a live and then archived webcast of the conference call and accompanying slides, available on the Company’s website. To listen to the archived audio file, visit our website http://www.euroseas.gr and click on Company Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

The slide presentation for the third quarter ended September 30, 2026, will also be available in PDF format minutes prior to the conference call and webcast, accessible on the company’s website (www.euroseas.gr) on the webcast page. Participants to the webcast can download the PDF presentation.

About
EuroseasLtd.

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 150 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA.
Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

After the sale of M/V Evridiki G, the Company will have a fleet of 20 vessels, including 14 Feeder containership and 6 Intermediate containerships with a cargo capacity of 58,588 teu. After the delivery of four intermediate and eight feeder containership newbuildings between 2027 and 2029, Euroseas’ fleet will consist of 32 vessels with a total carrying capacity of 94,840 teu.

Visit the Company’s website www.euroseas.gr

Company
Contact
 
Investor
Relations
/
Financial
Media

Tasos Aslidis
Chief Financial Officer Euroseas Ltd.
11 Canterbury Lane,
Watchung, NJ 07069
Tel. (908) 301-9091
E-mail: [email protected]

Nicolas Bornozis Markella Kara Capital Link, Inc.
230 Park Avenue, Suite 1540 New York, NY 10169
Tel. (212) 661-7566
E-mail: [email protected]



Posted on

Pinnacle and Raymond James expand strategic relationship to bring Synovus Securities advisors to RJFS

Pinnacle and Raymond James expand strategic relationship to bring Synovus Securities advisors to RJFS

Approximately 70 advisors with $18.7 billion in client assets under care expected to transition by May 2027

ATLANTA & ST. PETERSBURG, Fla.–(BUSINESS WIRE)–
Pinnacle Financial Partners, Inc. and Raymond James today announced an expansion of their longstanding strategic relationship. Approximately 70 financial advisors currently registered with Synovus Securities, Inc. will join the existing relationship between Pinnacle Asset Management and Raymond James Financial Services, bringing approximately $18.7 billion in client assets under care to the Raymond James platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112454284/en/

Synovus Securities is joining the Raymond James platform as Synovus merges with Pinnacle Financial Partners.

Synovus Securities is joining the Raymond James platform as Synovus merges with Pinnacle Financial Partners.

The transition is expected to be completed in May 2027 and follows the January 2026 combination of Pinnacle and Synovus Financial Corp. The advisors serve clients across the combined firm’s ten-state footprint and beyond, and they will continue to provide service through the transition. Once affiliated with Raymond James Financial Services, advisors will have access to Raymond James’ wealth management platform, technology and advisor support to provide a more modern experience as they support their clients’ most important financial decisions.

“This is a significant and highly strategic expansion of our longstanding relationship with Pinnacle Financial Partners,” said Stephen Kruchten, president of Raymond James’ Financial Institutions Division. “Pinnacle Asset Management has built one of the industry’s most respected wealth management programs, and we’re proud to have played a meaningful role in supporting that success. As we move forward with this substantial program expansion, we remain focused on providing the dedicated relationship management, advisor development resources, industry-leading technology and broad capabilities of Raymond James to help their advisors enhance productivity, deepen client relationships and drive long-term growth.”

Investment and wealth management capabilities have been part of Pinnacle’s client model since the firm’s founding, helping financial advisors bring specialists together around a client’s broader financial needs. Pinnacle Asset Management’s relationship with Raymond James has been central to that approach, pairing local advice and client relationships with Raymond James’ sophisticated investment platform and resources. The addition of Synovus Securities advisors extends that model across Pinnacle’s footprint.

“Our relationship with Raymond James is a key reason why we’re able to serve clients across their financial lives,” said Wayne Akins, head of wealth management at Pinnacle. “As we considered the right path for Synovus Securities, Inc. advisors and their clients, Raymond James stood out for its experience serving financial institutions with robust advisor support and broad capabilities. Bringing these teams into our existing relationship gives us a consistent foundation for wealth management across the combined firm and marks another important step in bringing Pinnacle and Synovus together.”

For clients, the transition is designed to provide continuity in their advisor relationships while connecting the expanded team to Raymond James’ investment and wealth management capabilities. For advisors, it brings the combined organization onto a common platform with dedicated relationship management, advisor development resources and technology. For Pinnacle and Raymond James, it expands an established relationship and strengthens the advisor and client experience.

About the Financial Institutions Division

The Financial Institutions Division was established by Raymond James in 1987 to provide banks and credit unions with an alternative to traditional third-party investment providers. Raymond James provides full-service securities brokerage and advisory services to financial institutions seeking to compete with the largest banks and securities firms in the country. In addition to a full complement of investment products and services, Raymond James has the ability to deliver investment banking, public finance, research, self-clearing capabilities and wealth management services to both individuals and institutions.

About Raymond James Financial Services

Raymond James Financial Services, Inc. (RJFS), member FINRA/SIPC, is a financial services firm supporting independent financial advisors nationwide. Since 1974, RJFS provides a wide range of investment and wealth planning-related services through its affiliate, Raymond James & Associates, Inc., member New York Stock Exchange/SIPC. Both firms are wholly owned subsidiaries of Raymond James Financial, Inc. (NYSE-RJF), one of the nation’s premier diversified financial services companies with financial advisors throughout the United States, Canada and overseas. Total client assets are approximately $1.94 trillion as of Sept. 30, 2026. Additional information is available at raymondjames.com.

About Pinnacle Financial Partners

Pinnacle Financial Partners, Inc. (“Pinnacle”) is a $129.1 billion asset regional bank which provides a full range of banking, investment, trust, mortgage and insurance products and services for commercial and consumer clients who want a comprehensive relationship with their financial institution. The firm joined forces with Synovus Financial Corp. in 2026, bringing together more than 160 years of combined banking service. Pinnacle is the largest bank headquartered in Tennessee and the largest bank holding company headquartered in Georgia. The firm is No. 1 in deposit market share* in the Nashville MSA and No. 4 in the Atlanta MSA with offices in Tennessee, Georgia, Florida, North Carolina, South Carolina, Alabama, Kentucky, Virginia and Maryland.

Pinnacle is an employer of choice for financial services professionals. The firm is No. 12 in the Fortune 100 Best Companies to Work For® in 2026, its 10th consecutive appearance. Pinnacle was also recognized by American Banker as No. 4 among America’s Best Banks to Work For in 2025, its 13th consecutive year on the list, and No. 1 among banks with more than $10 billion in assets. Learn more about Pinnacle at PNFP.com.

Securities offered through Raymond James Financial Services, Inc., member FINRA/SIPC, and are not insured by bank insurance, the FDIC or any other government agency, are not deposits or obligations of the bank, are not guaranteed by the bank, and are subject to risks, including the possible loss of principal. Pinnacle Financial Partners, Synovus Financial Corp. Synovus Securities, Inc. and Pinnacle Asset Management are not registered broker/dealers and are independent of Raymond James Financial Services. Investment advisory services offered through Raymond James Financial Services Advisors, Inc.

*As of June 30, 2026, according to FDIC data.

 

Joe Bass

(615) 743-8219

[email protected]

Tiffany Capuano

(678) 784-7111

[email protected]

KEYWORDS: United States North America Florida Georgia

INDUSTRY KEYWORDS: Personal Finance Technology Insurance Finance Fintech Consulting Banking Professional Services Software Asset Management

MEDIA:

Photo
Photo
Synovus Securities is joining the Raymond James platform as Synovus merges with Pinnacle Financial Partners.
Logo
Logo
Posted on

Modern Mining Announces Closing of its US$40 Million Reg A Initial Public Offering

Modern Mining Announces Closing of its US$40 Million Reg A Initial Public Offering

Common Shares to Begin Trading on NYSE American Under Ticker Symbol “MDRN” on November 13, 2026; Capital to Scale Recovery of Gold and Critical Metals from Electronic Waste

GREENVILLE, N.C.–(BUSINESS WIRE)–Modern Mining Technology Corp. (“Modern Mining” or the “Company”), which uses a proprietary aqueous-based process to recover gold and other valuable metals from electronic waste, today announced that it has closed its initial public offering (“IPO”), raising US$39,999,997 through the sale of 9,411,764 common shares (the “Common Shares”) at a public offering price of US$4.25 per share.

Modern Mining’s Common Shares are expected to begin trading on the NYSE American under the ticker symbol “MDRN” on November 13, 2026.

“We see electronic waste as an above-ground resource for gold, critical metals, and other valuable metals, with feedstock concentrations that can be significantly higher than traditionally mined ore,” said Jeet Basi, President and CEO of Modern Mining. “As the volume of e-waste continues to grow, so does the opportunity to recover more of those materials. The completion of our IPO gives us the resources to advance the next stage of our growth: increasing processing capacity, expanding our operations, and continuing to improve our technology. With the financing complete, our focus is on execution and scaling the business.”

Modern Mining uses a proprietary aqueous-based process to recover and concentrate gold and other valuable metals from discarded electronics. The Company sources e-waste from qualified suppliers and processes the material into concentrates that can be sold as partially refined products or further processed to isolate and enrich metals for sale into U.S. and international supply chains.

The Company sold 8,894,117 Common Shares in the United States and jurisdictions other than Canada through its Regulation A Tier 2 offering under the United States Securities Act of 1933, as amended, and 517,647 Common Shares in Canada pursuant to a long-form prospectus filed with the securities regulatory authorities in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario (collectively, the “Provinces”), which long-form prospectus also qualifies the Company’s Common Shares sold in the Regulation A Tier 2 offering and is available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The offering was hosted on Equifund.com. Digital Offering, LLC acted as the lead selling agent for the public offering in the United States, and Research Capital Corporation acted as the agent for the public offering in the Provinces.

About Modern Mining Technology Corp.

Modern Mining Technology Corp. is a resource recovery company focused on recovering valuable metals from electronic waste. The Company uses its proprietary aqueous-based processing technologies to extract, recover and produce precious and commodity metals, including gold, palladium, silver and copper and potentially 30 other metals. By processing end-of-life electronics, Modern Mining provides an alternative to traditional mining for sourcing valuable metals.

For more information about Modern Mining, visit https://modernmining.com/.

About Digital Offering, LLC:

Digital Offering, LLC (“Digital Offering”) is a next-generation investment bank and a leader in crowd-financed public offerings. The firm partners with high-quality private and public growth companies to access U.S. capital markets and achieve their growth objectives. With a strong focus on technology and innovation, Digital Offering applies traditional investment banking best practices to the Jumpstart Our Business Startups (JOBS) Act to maximize deal awareness and connect issuers with the right investors. Interested parties can learn more at digitaloffering.com.

FORWARD-LOOKING STATEMENTS:

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian securities laws. These statements relate to analysis and other information that are based on forecasts or future results, estimates of amounts not yet determinable and assumptions of management. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. We have based these forward-looking statements on information currently available to the Company, assumptions the Company believes are reasonable and our current expectations about future events or performance. While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. Our actual future results may differ materially from those discussed or implied in our forward-looking statements for various reasons. Factors that could contribute to such differences include, but are not limited to, our ability to maintain and increase feedstock of E-Waste supply commitments, the volume and composition of E-Waste feedstock, our ability to economically source, extract and recover E-Waste, our ability to successfully implement our growth strategy on a timely basis, the development of our Greenville, North Carolina facility, risks with respect to engineering, permitting, procurement, construction, commissioning and ramp-up, maintaining necessary permits, licenses or regulatory approvals required to operate or expand our business, changes in laws, regulations, market trends and competition in the Company’s industry, and the assumptions underlying any of the foregoing, and other factors discussed in the Company’s filings with the United States Securities and Exchange Commission (the “SEC”) under Regulation A. Consequently, all of the forward-looking statements are qualified by these cautionary statements, and there can be no assurances that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effect on, the Company. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release. The forward-looking statements contained in this news release are made only as of the date hereof. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. The Company encourages investors to review other factors that may affect its future results in the Company’s Offering Circular relating to this offering and its other filings with the SEC, available at www.sec.gov, and with the applicable Canadian securities regulators available at www.sedarplus.ca. This news release shall not constitute an offer to sell or the solicitation of any offer to buy the Company’s securities.

Investors
[email protected]

Media
[email protected]

Digital Offering
[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Recycling Consumer Electronics Mining/Minerals Environment Technology Sustainability Natural Resources

MEDIA:

Logo
Logo
Posted on

Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting

Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting

  • DAWNZERA showed sustained HAE attack rate reduction and long-term safety over two years
  • 71% HAE attack rate reduction maintained after two years on DAWNZERA compared to baseline for patients switching from another long-term prophylactic therapy
  • Treatment effect maintained regardless of dosing frequency every four or eight weeks

CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA® (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), to be presented at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona. Multiple presentations will demonstrate the long-term efficacy and safety of DAWNZERA in the OASISplus open-label extension (OLE) and switch cohorts over two years.

“People living with hereditary angioedema are faced with a chronic disease and need prophylactic therapy that will provide long-lasting disease control,” said Kenneth Newman, M.D., senior vice president, clinical development, Ionis. “These data demonstrate that DAWNZERA achieved durable efficacy and safety, not only when dosed every four weeks but also every eight weeks. In our switch study, patients who transitioned to DAWNZERA using a predefined protocol continue to experience lasting reductions in attack rates compared with baseline on their prior therapy.”

The OASISplus OLE cohort enrolled adult and adolescent patients continuing from the Phase 3 OASIS-HAE pivotal trial, who received DAWNZERA every four (Q4W) or every eight weeks (Q8W). A majority (84%) of patients remained in the study after two years, and patients in the OLE achieved a 95% overall reduction from baseline in HAE attack rates across both dosing groups (n=83).

The OASISplus switch cohort evaluated DAWNZERA in patients previously treated with lanadelumab, C1-esterase inhibitor or berotralstat who switched to DAWNZERA using a predefined protocol. After two years, 80% of patients remained in the switch cohort. Patients experienced an overall reduction in HAE attack rate of 71% from baseline on their prior long-term prophylactic therapy (n=64).

Ionis will also present a post hoc analysis of DAWNZERA in patients who were eligible to receive Q8W dosing in the OASISplus OLE and switch cohorts over two years of treatment. Patients who received DAWNZERA dosed every eight weeks at the start of the open-label extension maintained a 95% overall attack rate reduction over the two years, consistent with those who received DAWNZERA every four weeks.

Across these analyses, DAWNZERA maintained a favorable long-term safety and tolerability profile, with no new safety signals observed. The majority of treatment-emergent adverse events (TEAEs) were mild or moderate, with no serious TEAEs related to DAWNZERA.

All presentations are available on the Ionis website.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

Please see full Prescribing Informationfor DAWNZERA.

About Hereditary Angioedema (HAE)

HAE is a rare and potentially life-threatening genetic condition that involves recurrent attacks of severe swelling (angioedema) in various parts of the body, including the hands, feet, genitals, stomach, face and/or throat. HAE is estimated to affect approximately 7,000 people in the U.S.

About DAWNZERA® (donidalorsen)

DAWNZERA® (donidalorsen) is approved for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is an RNA-targeted medicine designed to target plasma prekallikrein (PKK), which plays an important role in activating inflammatory mediators associated with acute attacks of HAE. For more information about DAWNZERA, visit DAWNZERA.com.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has marketed medicines and a leading pipeline in neurology, cardiometabolic and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Forward-looking Statements

This press release includes forward-looking statements regarding Ionis’ business and the therapeutic and commercial potential of DAWNZERA, our commercial medicines, additional medicines in development and technologies and our expectations regarding development and regulatory milestones. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended December 31, 2025 and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our” and “us” all refer to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals® and DAWNZERA® are trademarks of Ionis Pharmaceuticals, Inc.

Ionis Investor Contact:
D. Wade Walke, Ph.D.
[email protected]
760-603-2331

Ionis Media Contact:
Hayley Soffer
[email protected]
760-603-4679

KEYWORDS: United States North America California Arizona

INDUSTRY KEYWORDS: Health Genetics General Health Clinical Trials Research Science Pharmaceutical

MEDIA:

Logo
Logo
Posted on

KalVista, a Company of the Chiesi Group, Reinforces Its Commitment to the Hereditary Angioedema (HAE) Community with New Real-World and Clinical Research Presented at the ACAAI Annual Meeting

KalVista, a Company of the Chiesi Group, Reinforces Its Commitment to the Hereditary Angioedema (HAE) Community with New Real-World and Clinical Research Presented at the ACAAI Annual Meeting

Scientific presentations highlight real-world patient experience, treatment satisfaction and quality-of-life outcomes with sebetralstat

The addition of sebetralstat to Chiesi’s rare immunology portfolio strengthens its long-term commitment to people living with rare conditions and their families

FRAMINGHAM, Mass.–(BUSINESS WIRE)–
KalVista Pharmaceuticals, Inc. (“KalVista”), a company of the Chiesi Group, today announced the presentation of new clinical and real-world research evaluating sebetralstat at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix (November 12-16). The five presentations highlight patient-reported satisfaction with sebetralstat, reasons for treatment switching, long-term health-related quality-of-life (QoL) outcomes, healthcare resource utilization among adolescents and clinician-reported caregiver burden. Together, these findings underscore the value of integrating real-world evidence and patient-reported outcomes to better evaluate the patient experience alongside treatment impact beyond conventional clinical trial endpoints. The research also reflects KalVista’s continued commitment to advancing hereditary angioedema (HAE) care, now as part of Chiesi Global Rare Diseases, with opportunities to build on broader rare disease capabilities and global reach.

“With our acquisition of KalVista Pharmaceuticals, the addition of sebetralstat to our rare immunology portfolio marks a major milestone in Chiesi’s longstanding commitment to rare disease communities,” said Giacomo Chiesi, Executive Vice President, Chiesi Global Rare Diseases. “As we build on KalVista’s deep expertise in HAE, close collaboration with the scientific and patient communities will remain essential to deepening our understanding of lived experiences and advancing care for people living with rare diseases today and for generations to come.”

The five presentations at ACAAI add to the growing body of clinical and real-world evidence evaluating sebetralstat, building on recent findings presented at the 2026 HAEi Regional Conference Americas and Bradykinin Symposium 2026. Together, these data provide further insights into clinical practice and patient-reported experiences, while reflecting continued progress in understanding the use of sebetralstat across the HAE community, including pediatric patients.

“Real-world evidence and patient-reported outcomes provide important insights into clinical practice and the everyday realities of managing HAE,” said William R. Lumry, MD, Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School and Medical Director of AARA Research Center, Dallas, Texas. ”Understanding patient satisfaction, treatment preferences and quality-of-life factors helps us better evaluate the full impact of disease management. As clinicians, we are encouraged by the ongoing research that expands our understanding of HAE across both adult and pediatric populations as it can help inform care and potentially expand treatment options.”

“The presentations at ACAAI reflect a research approach that looks beyond efficacy to the full treatment experience, including the emotional and practical factors that influence when and how people manage their attacks,” said Rachele Berria, MD, PhD, Senior Vice President, Medical Affairs, Chiesi Group. “The real-world evidence and quality-of-life data offer valuable perspective on the lived experiences of people with HAE and the considerations healthcare professionals need to take into account when making treatment decisions. These insights are increasingly important as we work to align treatment strategies with patient preferences and advance our clinical research across age groups.”

Beyond the data presented at these congresses, KalVista, now a company of the Chiesi Group, remains focused on advancing HAE care through continued research and collaboration with the scientific, clinical and patient communities. Together, KalVista and Chiesi are committed to building on this progress to help address the evolving needs of people living with HAE worldwide.

Details of presentations are as follows:

American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting

Abstract Title: Satisfaction with Sebetralstat for On-Demand Treatment of HAE Attacks: Real-World Data from the EARLY Study

Format: ePoster with Meet the Author presentations. All ePosters will be displayed and published online for viewing by meeting attendees using the ePosters Live System.

Presenter: Joshua S. Jacobs, MD, Medical Director of Allergy and Asthma Clinical Research, Inc., Walnut Creek, California.

Date/Time: Friday, November 13, 3:20 pm – 3:35 pm MT

  • EARLY is an ongoing phase 4, prospective, real-world, observational study evaluating the effectiveness of sebetralstat in adolescents and adults with HAE. This presentation will highlight patient satisfaction data from completed HAE attack eDiaries that were prospectively collected (January-June 2026) from US participants aged ≥12 y who had been prescribed or were taking sebetralstat for 3 months before enrollment.

Abstract Title: Reasons for Switching to Oral Sebetralstat for HAE Attacks: Real-World Data from the EARLY Study

Format: ePoster with Meet the Author presentations. All ePosters will be displayed and published online for viewing by meeting attendees using the ePosters Live System.

Presenter: William R. Lumry, MD,Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School and Medical Director of AARA Research Center, Dallas, Texas.

Date/Time: Friday, November 13, 5:05 pm – 5:20 pm MT

  • EARLY is an ongoing phase 4, prospective, real-world, observational study evaluating the effectiveness of sebetralstat in adolescents and adults with HAE. This presentation will highlight baseline data on reasons for switching to sebetralstat, collected from 56 US participants ≥12 y who had been prescribed or were taking sebetralstat for on-demand treatment of HAE attacks for 3 months before enrollment.

Abstract Title: Treatment and Healthcare Resource Utilization in Adolescent Patients with Hereditary Angioedema: US Claims Database Analysis

Format: ePoster with Meet the Author presentations. All ePosters will be displayed and published online for viewing by meeting attendees using the ePosters Live System.

Presenter: Adil Adatia, MD, Assistant Professor in the Department of Medicine at the University of Alberta, Edmonton, Alberta, Canada.

Date/Time: Friday, November 13, 5:35 pm – 5:50 pm MT

  • This study characterized real-world use of on-demand treatments and healthcare resource utilization among adolescent patients aged 12 to 17 years old living with HAE. This presentation will highlight data collected from the IQVIA PharMetrics® Plus Closed Health Plan Claims Database (study period: January 1, 2021 – December 31, 2024) to evaluate patterns that may help inform strategies to optimize disease management and reduce healthcare burden.

Abstract Title: Improvement in Health-related Quality of Life with Sebetralstat for HAE Attacks in Adolescents and Adults

Format: ePoster with Meet the Author presentations. All ePosters will be displayed and published online for viewing by meeting attendees using the ePosters Live System.

Presenter: Jonathan A. Bernstein, MD, Professor of Medicine, University of Cincinnati College of Medicine and Investigator at Bernstein Clinical Research Center, Cincinnati, Ohio.

Date/Time: Saturday, November 14, 11:45 am – 12:00 pm MT

  • KONFIDENT-S is a 2-year open-label extension study, in which participants completed the angioedema quality of life (AE-QoL) questionnaire at the Enrollment Visit (baseline) and in the eDiary every 28 (± 7) days thereafter. This presentation will highlight data on health-related quality of life (QoL) from adolescent and adult participants who treated attacks with sebetralstat.

Abstract Title: Impact of Injectable HAE On-demand Treatments on Children and Caregivers: a Clinician Interview Study

Format: ePoster with Meet the Author presentations. All ePosters will be displayed and published online for viewing by meeting attendees using the ePosters Live System.

Presenter: Timothy J. Craig, DO, Professor, Department of Medicine, The Pennsylvania State University, Hershey, Pennsylvania.

Date/Time: Sunday, November 15, 12:15 pm – 12:30 pm MT

  • This presentation will highlight findings of targeted literature review and interviews with clinical experts in HAE to understand the impact of HAE and the burden of injectable on-demand treatment on children aged ≤11 years and their caregivers.

About EKTERLY® (sebetralstat)

EKTERLY (sebetralstat) is a novel plasma kallikrein inhibitor approved in the United States, European Union, United Kingdom, Switzerland, Australia, Singapore and Japan for the treatment of acute attacks of hereditary angioedema (HAE) in people 12 years of age and older. For more information, including the full US Prescribing Information, visit EKTERLY.com.

INDICATION

EKTERLY® (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION

Adverse reactions: The most commonly reported adverse reaction was headache (3.2%).

Drug interactions: EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions. Avoid use of EKTERLY with strong CYP3A4 inhibitors and reduce the dose of EKTERLY to one dose of 300 mg (one tablet) with moderate CYP3A4 inhibitors. Concomitant use of EKTERLY with a strong or moderate CYP3A4 inducer decreases sebetralstat exposure, which may decrease efficacy. The use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.

Use in specific populations: Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C). The recommended dosage of EKTERLY is one dose of 300 mg (one tablet) in patients with moderate hepatic impairment (Child-Pugh Class B). There are no available data on EKTERLY in pregnant women to evaluate for a drug associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

There are no data on the presence of sebetralstat or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.

The safety and effectiveness of EKTERLY in pediatric patients aged under 12 years of age have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact KalVista Pharmaceuticals, Inc. at 1-855-258-4782 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the fullPrescribing Information.

About Hereditary Angioedema

Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. Treatment guidelines recommend treating attacks as early as possible to prevent progression of swelling and shorten the time to attack resolution, and to consider treatment for all attacks, regardless of anatomic location or severity.

About KalVista Pharmaceuticals, Inc.

KalVista, a company of the Chiesi Group, is a global pharmaceutical company dedicated to delivering oral therapies for people affected by rare diseases with significant unmet needs. The KalVista team discovered and developed sebetralstat for hereditary angioedema (HAE) and continues to work closely with the global HAE community to improve treatment and care worldwide. As part of Chiesi Global Rare Diseases, a Chiesi Group business unit established to deliver innovative therapies and solutions for people living with rare diseases, KalVista is building on its expertise in HAE and contributing to a shared mission to help underserved rare disease communities live their most fulfilling lives.

For more information, please visit www.kalvista.com and www.chiesirarediseases.com.

Media Contact

Chiara Travagin, Head of Global Communications, Rare Diseases

[email protected]

Tel: +39 348.8818985

KEYWORDS: United States North America Arizona Massachusetts

INDUSTRY KEYWORDS: Health General Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo